Anna Belenciuc

Anna Belenciuc

Auto-generated profile, based on publicly available information

Anna Belenciuc


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Closed access
MEMargarita Eversdijk
Margarita Eversdijk
MSMarina Sangheli
Marina Sangheli
VLVitalie Lisnic
Vitalie Lisnic
VSVictoria Simon
Victoria Simon
ABAnna Belenciuc
Anna Belenciuc
Ocrelizumab, a humanized monoclonal antibody that targets CD20-positive B cells, has significantly advanced the treatment of multiple sclerosis (MS). Approved for both relapsing-remitting MS and primary progressive MS, it represents a novel approach in MS therapy. Since the end of 2023, Republic of Moldova has incorporated ocrelizumab into its national treatment guidelines, providing access to this innovative therapy for its population. This review provides a detailed analysis of ocrelizumab’s mechanism of action, clinical efficacy, safety profile, and long-term impact based on data from clinical trials and real-world studies. Additionally, the review explores ocrelizumab’s comparison with other disease-modifying therapies, its role in patient quality of life, and the future direction of MS treatment.

1 November 2025
Verified
Journal Article
Closed access
EPEcaterina Postovoi
Ecaterina Postovoi
CCCristina Cerguta
Cristina Cerguta
ABAnna Belenciuc
Anna Belenciuc
VLVitalie Lisnic
Vitalie Lisnic
MSMarina Sangheli
Marina Sangheli
Vestibular disorders in multiple sclerosis: clinical and management aspects (narrative review). Vestibular disorders are a frequent and disabling manifestation in multiple sclerosis (MS), with complex pathophysiological mechanisms involving both central structures and associations with peripheral vestibulopathies, such as benign paroxysmal positional vertigo (BPPV). Objective of the study. To perform a detailed evaluation of the specialized literature in order to analyze the relationships between the clinical forms of MS, lesion topography, types of vestibular syndromes, functional markers, and treatment options. Materials and Methods. Literature synthesis, conducted in accordance with PRISMA, of 39 articles published between 2015-2025 in English in PubMed, Elsevier, Frontiers, and ResearchGate. Results. Relapsing-remitting MS (RRMS) is more frequently associated with acute/episodic vestibular syndromes related to new lesions in the brainstem/vestibulo-cerebellar region, while progressive forms present with chronic vestibular syndrome. vHIT, VEMP, VNG, and posturography correlate with MS severity and progression. Effective interventions include personalized vestibular rehabilitation, repositioning maneuvers for peripheral forms, and early treatment of relapses. Recent studies support the benefits of VR-based therapy and integrated rehabilitation programs in improving balance and reducing dizziness. Conclusions. An integrated approach, guided by phenotype and objective markers, optimizes the differential diagnosis of vestibular disorders in multiple sclerosis and the personalization of therapy/rehabilitation, with potential to reduce dizziness, improve balance, and lower the risk of falls.

1 September 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
ABAnna Belenciuc
Anna Belenciuc
ABAna-Maria Bubuioc
Ana-Maria Bubuioc
OOOlesea Odainic
Olesea Odainic
MSMarina Sangheli
Marina Sangheli
MGMihail Gavriliuc
Mihail Gavriliuc
VLVitalie Lisnic
Vitalie Lisnic
Background: Multiple sclerosis (MS) is a disease that affects young people of reproductive age (20-40 years old), predominantly women. Therefore, almost every patient has questions about pregnancy and breastfeeding. Family planning is one of the key issues in the choice of treatment tactics. Despite the growing number of therapeutic options for individualized treatment, it is still a question how to manage women with MS who become pregnant while taking disease-modifying drugs or want to become pregnant after starting this treatment. Conclusions: Women with MS should not be discouraged from pregnancy due to their illness. It is necessary to proactively discuss pregnancy planning with all women with MS of childbearing age. Based on available data, interferon beta and glatiramer acetate appear to be most suitable for use up until the time of confirmed pregnancy. A large amount of data (more than 1000 cases) obtained from registries shows that use of interferon beta before conception and during pregnancy suggests no evidence of increase in the rate of congenital anomalies or spontaneous abortions. For women with persistent high disease activity, pulsed immune reconstitution therapy gives additional opportunity for family planning after the last dose. The choice between available options for pulsed immune reconstitution therapy should be based on efficacy balanced against the risks.

1 March 2026 in Moldovan Journal of Health Sciences
Verified
Journal Article
Open access
ABAnna Belenciuc
Anna Belenciuc
OOOlesea Odainic
Olesea Odainic
MSMarina Sangheli
Marina Sangheli
EMElena Manole
Elena Manole
Carmen Adella SirbuCarmen Adella Sirbu
Carmen Adella Sirbu
VLVitalie Lisnic
Vitalie Lisnic
Introduction. The therapeutic landscape of multiple sclerosis has undergone a remarkable transformation over the past two decades. The paradigm has shifted from reliance on moderate-efficacy, first-generation injectable therapies toward earlier adoption of high-efficacy disease-modifying treatments, particularly in relapsing forms of MS. This evolution reflects an increasing focus on early intensive treatment strategies aimed at preserving long-term neurological function and brain health. Materials and methods. This narrative review synthesizes recent global evidence on progress in disease-modifying treatments across all multiple sclerosis phenotypes, drawing from randomized controlled trials, real-world studies, and expert consensus guidelines. In addition, it includes a comparative health policy analysis assessing DMT availability, access, and implementation in Romania and the Republic of Moldova, based on national formularies, reimbursement frameworks, and care delivery models. Results. Globally, the MS treatment algorithm has been reoriented toward early intensive treatment, supported by emerging evidence favoring high-efficacy therapies in the early disease course. While many countries have aligned their protocols accordingly, regional discrepancies persist. Romania, as an EU member, has expanded patient access to 16 reimbursed therapies and biomarker-driven monitoring, and has developed a network of specialized Multiple Sclerosis centers. Conversely, the Republic of Moldova faces structural and economic barriers that restrict access to high-efficacy treatments, advanced diagnostics, and multidisciplinary care - factors contributing to delayed treatment and suboptimal outcomes. Conclusions. Understanding both global innovations and regional realities is necessary to place current Multiple Sclerosis care in context. Further advancements in science, health policy, and infrastructure will ultimately determine how effectively different nations can convert therapeutic progress into actual improvements in patient outcomes.